A
Alexis B. Cortot
Researcher at Pasteur Institute
Publications - 199
Citations - 6691
Alexis B. Cortot is an academic researcher from Pasteur Institute. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 27, co-authored 151 publications receiving 4900 citations. Previous affiliations of Alexis B. Cortot include University of Lille Nord de France & Lille University of Science and Technology.
Papers
More filters
Journal ArticleDOI
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
Wenjun Zhou,Dalia Ercan,Liang Chen,Cai-Hong Yun,Danan Li,Marzia Capelletti,Alexis B. Cortot,Lucian R. Chirieac,Roxana E. Iacob,Robert F. Padera,John R. Engen,Kwok-Kin Wong,Michael J. Eck,Nathanael S. Gray,Pasi A. Jänne,Pasi A. Jänne +15 more
TL;DR: It is demonstrated that functional pharmacological screens against clinically important mutant kinases represent a powerful strategy to identify new classes of mutant-selective kinase inhibitors that may be clinically more effective and better tolerated than quinazoline-based inhibitors.
Journal ArticleDOI
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
Jean-Charles Soria,Daniel Shao-Weng Tan,Rita Chiari,Yi-Long Wu,Luis Paz-Ares,Juergen Wolf,Sarayut Lucien Geater,Sergey Orlov,Diego Cortinovis,Chong-Jen Yu,Maximillian Hochmair,Alexis B. Cortot,Chun-Ming Tsai,Denis Moro-Sibilot,Rosario Garcia Campelo,Tracey McCulloch,Paramita Sen,Margaret Dugan,Serafino Pantano,Fabrice Branle,Cristian Massacesi,Gilberto de Castro +21 more
TL;DR: First-line ceritinib showed a statistically significant and clinically meaningful improvement in progression-free survival versus chemotherapy in patients with advanced ALK-rearranged NSCLC.
Journal ArticleDOI
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
Julien Mazieres,Alexander Drilon,Amélie Lusque,Laurent Mhanna,Alexis B. Cortot,Laura Mezquita,A. Thai,C. Mascaux,Sébastien Couraud,Remi Veillon,M. van den Heuvel,Joel W. Neal,Nir Peled,Martin Früh,Terry L. Ng,Valérie Gounant,Sanjay Popat,Joachim Diebold,Joshua K. Sabari,Viola W. Zhu,Sacha I. Rothschild,Paolo Bironzo,Alex Martinez-Marti,Alessandra Curioni-Fontecedro,Rafael Rosell,Mickaël Lattuca-Truc,Marcel Wiesweg,Benjamin Besse,Benjamin Solomon,Fabrice Barlesi,R.D. Schouten,Heather A. Wakelee,D.R. Camidge,Gérard Zalcman,Silvia Novello,S-H.I. Ou,Julie Milia,Oliver Gautschi +37 more
TL;DR: In certain subgroups, PFS was positively associated with PD-L1 expression (KRAS, EGFR) and with smoking status (BRAF, HER2) and the lack of response in the ALK group was notable.
Journal ArticleDOI
Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives
Julien Mazieres,Solange Peters,Benoit Lepage,Alexis B. Cortot,Fabrice Barlesi,Michèle Beau-Faller,Benjamin Besse,Hélène Blons,Audrey Mansuet-Lupo,Thierry Urban,Denis Moro-Sibilot,Eric Dansin,Christos Chouaid,Marie Wislez,Joachim Diebold,Enriqueta Felip,Isabelle Rouquette,Julie Milia,Oliver Gautschi +18 more
TL;DR: This study, the largest to date dedicated to Her2-mutated NSCLC, reinforces the importance of screening for HER2 mutations in lung adenocarcinomas and suggests the potential efficacy of HER2-targeted drugs in this population.
Journal ArticleDOI
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kazuhiko Nakagawa,Edward B Garon,Takashi Seto,Makoto Nishio,Santiago Ponce Aix,Luis Paz-Ares,Chao-Hua Chiu,Keunchil Park,Silvia Novello,Ernest Nadal,Fumio Imamura,Kiyotaka Yoh,Jin-Yuan Shih,Kwok Hung Au,Denis Moro-Sibilot,Sotaro Enatsu,Annamaria Zimmermann,Bente Frimodt-Moller,Carla Visseren-Grul,Martin Reck,Quincy Chu,Alexis B. Cortot,Jean-Louis Pujol,Elizabeth Fabre,Corinne Lamour,Helge Bischoff,Jens Kollmeier,M Kimmich,Walburga Engel-Riedel,Stefan Hammerschmidt,Wolfgang Schütte,Konstantinos N. Syrigos,James Chung-Man Ho,Kwok-Hung Au,Andrea Ardizzoni,Giulia Pasello,Vanessa Gregorc,Alessandro Del Conte,Domenico Galetta,Toshiaki Takahashi,Toru Kumagai,Katsuyuki Hotta,Yasushi Goto,Yukio Hosomi,Hiroshi Sakai,Yuichi Takiguchi,Young Hak Kim,Takayasu Kurata,Hiroyuki Yamaguchi,Haruko Daga,Isamu Okamoto,Miyako Satouchi,Satoshi Ikeda,Kazuo Kasahara,Shinji Atagi,Koichi Azuma,Keisuke Aoe,Yoshitsugu Horio,Nobuyuki Yamamoto,Hiroshi Tanaka,Satoshi Watanabe,Naoyuki Nogami,Tomohiro Ozaki,Ryo Koyama,Tomonori Hirashima,Hiroyasu Kaneda,Keisuke Tomii,Yuka Fujita,Masahiro Seike,Naoki Nishimura,Terufumi Kato,Masao Ichiki,Hideo Saka,Katsuya Hirano,Yasuharu Nakahara,Shunichi Sugawara,Sang-We Kim,Young Joo Min,Hyun Woo Lee,Jin-Hyoung Kang,Ho Jung An,Ki Hyeong Lee,Jin Soo Kim,Gyeong-Won Lee,Sung Yong Lee,A. Alexandru,Anghel Adrian Udrea,Óscar Juan-Vidal,Ernest Nadal-Alforja,Ignacio Gil-Bazo,Santiago Ponce-Aix,Belén Rubio-Viqueira,Miriam Alonso Garcia,Enriqueta Felip Font,Jose Fuentes Pradera,Juan Coves Sarto,Meng-Chih Lin,Wu Chou Su,Te Chun Hsia,Gee-Chen Chang,Yu-Feng Wei,Jian Su,Irfan Cicin,Tuncay Göksel,Hakan Harputluoglu,Ozgur Ozyilkan,Ivo Henning,Sanjay Popat,Olivia Hatcher,Kathryn Mileham,Jared Acoba,Edward B. Garon,Gabriel Jung,Moses Sundar Raj,William J. Martin,Shaker R. Dakhil +115 more
TL;DR: The RELAY trial as mentioned in this paper evaluated erlotinib, an EGFR tyrosine kinase inhibitor (TKI) standard of care, plus ramucirumab, a human IgG1 VEGFR2 antagonist, or placebo in patients with untreated EGFR-mutated metastatic NSCLC.